Advanced Filters
noise

Aspergillosis Clinical Trials

A listing of Aspergillosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,098 clinical trials
X Xinru Li

99mTc-P137 SPECT/CT in Prostate Cancer

Purpose: This study will take prostate specific membrane antigen (PSMA) as the targeting of radionuclide labeled molecular probe to explore the diagnostic efficacy of 99mTc-P137 radioactive probe in prostate cancer. Combining with SPECT/CT to optimize the imaging, image analysis and clinical diagnosis process of 99mTc-P137 probe, the aim of the …

18 years of age Male Phase N/A
S Shaoli Song, M.D.

Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary efficacy of Lutetium Lu 177 JH020002 Injection in adult patients with advanced prostate cancer.

18 years of age Male Phase 1/2
T Tharakeswara Bathala

Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)

Multiparametric MRI (mpMRI) of the prostate is an important tool for diagnosis of clinically significant prostate cancer (csPCa) in men with an elevated serum prostate specific antigen, which can decrease the rate of unnecessary biopsies and reduce the incidence of over-diagnosis of non-csPCa. Furthermore, there is evidence that MRI is …

18 years of age All Phase N/A
G GU Onc Research Team

Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). The hypothesis for this trial is that cabozantinib has anti-tumor activity in a molecularly-selected group of patients with CRPC.

18 - 99 years of age Male Phase 2

Diagnostic Performance of PSMA PET/CT for Pre-operative Lymph Node Assessment in Intermediate and High-risk Non-metastasic Prostate Cancer (PREOP-PSMA ).

In France, prostate cancer is the most common cancer in men over 50 years of age (nearly 50,000 new cases per year) and is the second most common cause of cancer death in men (approximately 9,000 deaths per year). Although mortality has been declining since the end of the 1990s …

18 years of age Male Phase 2
A Andrew Loblaw, MD

2 Ablative RadioTherapy Treatments for Prostate Cancer

Favorable-risk prostate cancer represent a large proportion of patients diagnosed with prostate cancer and image guided radiation therapy (IGRT) is commonly used to treat these patients using protracted courses of up to 39 treatments over 8 weeks. Stereotactic ablative body radiotherapy (SABR) protocols hold the promise of more convenience, less …

years of age Male Phase 2/3
I Isabelle Thibault, MD, FRCPC

A Trial Evaluating Toxicity of SBRT and LDRB in Localized Prostate Cancer.

The goal of this clinical trial is to compare SBRT (Stereotactic Body RadioTherapy) to LDRB (Low-Dose Rate Brachytherapy with Iodine-125 seed implant) in patients with low and favourable intermediate-risk prostate cancer. The two main questions it aims to answer are : Does SBRT (Stereotactic Body RadioTherapy) for low and intermediate …

18 years of age Male Phase N/A
M Margaret Tovar

Men Moving Forward: A Lifestyle Program for African-American Prostate Cancer Survivors

This study will examine the efficacy of Men Moving Forward (MMF), a four-month community-based lifestyle intervention designed for AA PC survivors. MMF is rooted in the evidence-based Moving Forward lifestyle intervention developed with and for AA breast cancer survivors. This intervention was adapted in collaboration with AA PC survivors. It …

18 years of age Male Phase N/A
P Paul SARGOS, MD

Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer

Randomized non-comparative phase II trial to assess the preliminary signs of antitumor activity of darolutamide plus radiation therapy in patients with unfavorable intermediate risk prostate cancer.

18 years of age Male Phase 2
G Giuseppe Sanguineti, Professor

Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer

This is a prospective, open, randomized phase II trial.

18 - 90 years of age Male Phase 2

Simplify language using AI